NCT07179445
- Conditions
- NSCLC
- Locations
-
- Tianjin Medical University Cancer Institute and Hospital(Lead Center) Tianjin, China
Clinical trial condition
NSCLC
Explore clinical trials studying NSCLC. Study availability and eligibility vary by location and protocol.
357 public trials
121 recruiting studies
NSCLC trial results
Not Yet Recruiting
Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)
NCT07156604
- Conditions
- NSCLC, Neoadjuvant Therapy
- Locations
-
- Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Not Yet Recruiting
Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer
NCT07153770
- Conditions
- MET Activating Mutation, MET Exon 14 Mutation, NSCLC
- Locations
-
Not specified
Not Yet Recruiting
QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC
NCT07134413
- Conditions
- NSCLC
- Locations
-
Not specified
Not Yet Recruiting
A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
NCT07086326
- Conditions
- AK112, Bispecific Antibody, Immunotherapy, +2 more
- Locations
-
- Peking University People's Hospital Beijing, Beijing Municipality, China
- Hunan Cancer Hospital Changsha, Hunan, China
- Shanghai Chest Hospital Shanghai, Shanghai Municipality, China
- The First Affiliated Hospital of Xi'an Jiaotong University Xi’an, Shanxi, China
Not Yet Recruiting
Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
NCT05909137
- Conditions
- Immunotherapy, Intensity Modulated Radiation Therapy, NSCLC, +1 more
- Locations
-
Not specified
Not Yet Recruiting
Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC
NCT07035392
- Conditions
- Adebrelimab (SHR-1316), Chemotherapy, NSCLC
- Locations
-
Not specified
NCT06893354
- Conditions
- NSCLC
- Locations
-
Not specified
Not Yet Recruiting
The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage I ALK-positive NSCLC Patients with High Risk Factors
NCT06772610
- Conditions
- ALK, Adjuvant Treatment, NSCLC, +1 more
- Locations
-
Not specified
Not Yet Recruiting
Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs
NCT06766591
- Conditions
- AK112, Central Nervous System Neoplasms, Chemotherapy, +9 more
- Locations
-
Not specified